Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone.

ABSTRACT:

Introduction

Uric acid and edaravone might exert a neuroprotective effect in amyotrophic lateral sclerosis (ALS) by reducing oxidative stress. We analyzed whether the treatment effect of edaravone is pronounced in patients whose uric acid level increased after the treatment with edaravone.

Materials and methods

Forty patients with ALS who underwent treatment with edaravone were included. Baseline uric acid level and the rate of decline in uric acid after edaravone treatment were recorded. The rate of change of ALS functional rating scale-revised (ΔALSFRS-R/month) was calculated based on baseline ALSFRS-R score and ALSFRS-R score 6-24 weeks after the treatment.

Results

The serum uric acid levels decreased after treatment in 26 (65%) patients and increased in 12 (30%) p

SUBMITTER: Han HJ 

PROVIDER: S-EPMC8933037 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature